Explore

Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial
Trendline Trendline
Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment

Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment

Allarity Therapeutics Advances Stenoparib with Phase 3 Manufacturing Campaign for Cancer Treatment
Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Trendline Trendline
Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026

Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026

Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data